Aim: To develop new therapies for prostate cancer, disease heterogeneity must be
addressed. This includes patient variation, multi-focal disease, cellular heterogeneity …

Background Prostate cancer is a broad-spectrum disease, spanning from indolent to a
highly aggressive lethal malignancy. Prostate cancer cell lines are essential tools to …

The ability of a population of PC3 prostate epithelial cancer cells to become resistant to
docetaxel therapy and progress to a mesenchymal state remains a fundamental problem …

Choosing an appropriate cell model (s) is the first decision to be made before starting a new
project or programme of study. Here, we address the rationale that can be behind this …

Prostate cancers have a justified reputation as one of the most heterogeneous human
tumours. Indeed, there are some who consider that advanced and castration-resistant …

Prostate cancer (PCa) is the second most commonly diagnosed malignancy in men and has
an extremely heterogeneous clinical behaviour. The vast majority of PCas are hormonally …

Introduction The 2018 Coffey‐Holden Prostate Cancer Academy (CHPCA) Meeting,“Tumor
Cell Heterogeneity and Resistance,” was held in Los Angeles, California from June 21 to 24 …

Prostate cancer is characterized by a high degree of heterogeneity, which poses a major
challenge to precision therapy and drug development. In this review, we discuss how …

Tumor heterogeneity plays a key role in prostate cancer prognosis, therapy selection,
relapse, and acquisition of treatment resistance. Prostate cancer presents a heterogeneous …

In 2023, approximately 288,300 new diagnoses of prostate cancer will occur, with 34,700
disease-related deaths. Death from prostate cancer is associated with metastasis, enabled …